Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study

Neurology

Volumn 73, Issue 18, 2009, Pages 1485-1492

  Pachner, Andrew R ^a   Cadavid, Diego ^a   Wolansky, Leo ^a   Skurnick, Joan ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETASERON COPAXONE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; INCIDENCE; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES; CONTRAST MEDIA; DRUG TOLERANCE; FEMALE; GADOLINIUM; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449380035     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bf9919     Document Type: Article

References (39)

1. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;CD002002.
2. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552. (Pubitemid 36207471)
3. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
4. Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 2006;66:444-446.
5. Pachner A, Narayan K, Price N, et al. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003;7:17-25.
6. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bio-activity (ADB). Neurology 2003;61:S24-S26.
7. Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuro-immunol 2005;166:180-188.
8. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67: 1681-1683.
9. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65:40-47.
10. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of multiple sclerosis with Betaseron or Copaxone by monthly brain MRI. Neurology 2009;72:1976-1983.
11. Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging 2005;15: 289-290.
12. Cadavid D, Cheriyan J, Skurnick J, et al. New acute and chronic black holes in multiple sclerosis patients randomized to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry Epub ahead of print 2009 Aug 16.
13. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003;61:1444-1446.
14. Ross C, Clemmesen KM, Svenson M, et al. Immunogenic-ity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-712.
15. Freedman MS, Pachner AR. Neutralizing antibodies to biological therapies: a "touch of gray" vs a "black and white" story. Neurology 2007;69:1386-1387.
16. Gilli F, Marnetto F, Caldano M, et al. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. J Neuroimmunol 2007;192:198-205.
17. Gilli F, Marnetto F, Stefanuto G, et al. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Di-agn 2004;8:185-194.
18. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12: 817-827.
19. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
20. van der Voort L, Kok A, Visser A, et al. Interferon-/3 bio-activity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 2009;15:212-218.
21. Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 2004;17:241-246. (Pubitemid 38720974)
22. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact-an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-984.
23. Frank JA, Richert N, Bash C, et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-725.
24. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55.
25. Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007;35:173-187.
26. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39.
27. Deisenhammer F, Mayringer I, Harvey J, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000;54:2055-2060.
28. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
29. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. Immunogenicity of interferon beta: differences among products. J Neurol 2004;251(suppl 2):II15-II24.
30. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-1279.
31. Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN-/3 restored after the disappearance of neutralizing antibodies? Mult Scler 2008;14: 837-842.
32. Richert ND, Zierak MC, Bash CN, et al. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000;6:86-90.
33. Vartanian T, Solberg Sorensen P, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol 2004;251(suppl 2): II25-II30.
34. Martinez-Yelamos S, Martinez-Yelamos A, Martin Ozaeta G, et al. Regression to the mean in multiple sclerosis. Mult Scler 2006;12:826-829.
35. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115: 152-160.
36. Rudick RA. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 2003;61:S31-S34.
37. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-1272.
38. Pachner A, Brady J, Narayan K, Steiner I. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J Neurol 2008;255: 1815-1817.
39. Millonig A, Rudzki D, Holzl M, et al. High-dose Intravenous Interferon Beta in Patients with Neutralizing Antibodies (HINABS): a pilot study. Mult Scler 2009;15:977-983